Table 5.
Multivariable Poisson regression for receipt of neoadjuvant chemotherapy in patients diagnosed 2010–2012.
| Borderline lumpectomy-eligible patients |
Locally-advanced patients | |||
|---|---|---|---|---|
| aRR (95% CI) for stage IIA (T2N0 only), IIB, and IIIA (T3N1 only) |
P value | aRR (95% CI) for stage IIIA (T0-3N2 only), IIIB, and IIIC |
P value | |
| Age (years) | ||||
| <50 | 1 | 1 | ||
| 50–54 | 0.87 (0.84, 0.90) | <.001 | 0.96 (0.92, 0.99) | .02 |
| 55–59 | 0.83 (0.80, 0.86) | <.001 | 0.93 (0.89, 0.97) | <.001 |
| 60–64 | 0.69 (0.66, 0.72) | <.001 | 0.86 (0.82, 0.90) | <.001 |
| Race | ||||
| White non-Hispanic | 1 | 1 | ||
| Black non-Hispanic | 1.02 (0.98, 1.05) | .41 | 1.06 (1.02, 1.10) | .002 |
| Hispanic | 1.01 (0.96, 1.06) | .83 | 1.01 (0.96, 1.07) | .63 |
| Other | 0.98 (0.92, 1.04) | .45 | 1.05 (0.98, 1.13) | .18 |
| Insurance status | ||||
| Private | 1 | 1 | ||
| Medicaid | 1.01 (0.97, 1.05) | .64 | 0.97 (0.94, 1.01) | .13 |
| Other government | 0.96 (0.86, 1.07) | .43 | 0.94 (0.82, 1.08) | .35 |
| None or unknown | 1.05 (1.00, 1.11) | .06 | 0.99 (0.94, 1.04) | .64 |
| Year of Diagnosis | ||||
| 2010 | 1 | 1 | ||
| 2011 | 1.09 (1.05, 1.12) | <.001 | 1.05 (1.01, 1.09) | .009 |
| 2012 | 1.12 (1.09, 1.16) | <.001 | 1.09 (1.05, 1.13) | <.001 |
| Charlson/Deyo Comorbidity Score | ||||
| 0 | 1 | 1 | ||
| 1 | 0.86 (0.82, 0.91) | <.001 | 0.93 (0.89, 0.98) | .006 |
| 2+ | 0.72 (0.62, 0.83) | <.001 | 0.85 (0.73, 0.98) | .02 |
| Facility region | ||||
| South | 1 | 1 | ||
| Midwest | 0.96 (0.92, 0.99) | .005 | 1.02 (0.99, 1.06) | .24 |
| Northeast | 0.88 (0.85, 0.91) | <.001 | 0.90 (0.86, 0.94) | <.001 |
| West | 0.91 (0.88, 0.95) | <.001 | 0.98 (0.93, 1.02) | .33 |
| Facility type | ||||
| Academic/research | 1 | 1 | ||
| Comprehensive community cancer program | 0.90 (0.88, 0.93) | <.001 | 0.92 (0.90, 0.95) | <.001 |
| Community cancer program | 0.73 (0.69, 0.77) | <.001 | 0.78 (0.74, 0.83) | <.001 |
| Population density | ||||
| Rural | 1 | 1 | ||
| Non-rural | 1.13 (1.01, 1.28) | .04 | 1.01 (0.89, 1.13) | .93 |
| Tumor grade | ||||
| 1 | 1 | 1 | ||
| 2 | 1.24 (1.16, 1.33) | <.001 | 1.17 (1.05, 1.29) | .003 |
| 3+ | 1.21 (1.13, 1.30) | <.001 | 1.17 (1.06, 1.29) | .003 |
| HR/HER2 summary | ||||
| HR+/HER2− | 1 | 1 | ||
| HR+/HER2+ | 1.50 (1.44, 1.55) | <.001 | 1.06 (1.01, 1.10) | .02 |
| HR−/HER2+ | 1.69 (1.62, 1.77) | <.001 | 1.17 (1.12, 1.22) | <.001 |
| HR−/HER2− | 1.70 (1.65, 1.77) | <.001 | 1.22 (1.17, 1.27) | <.001 |
| AJCC Clinical Stage | ||||
| IIA (T2N0 only) | 1 | - | ||
| IIB | 2.49 (2.41, 2.57) | <.001 | - | |
| IIIA (T3N1 only) | 3.91 (3.78, 4.04) | <.001 | - | |
| IIIA (T0-3N2 only) | - | 1 | ||
| IIIB non-inflammatory | - | 1.62 (1.55, 1.69) | <.001 | |
| IIIC non-inflammatory | - | 1.20 (1.14, 1.26) | <.001 | |
| Inflammatory (T4d) | - | 1.86 (1.79, 1.94) | <.001 | |
| Histology | ||||
| Invasive ductal carcinoma | 1 | 1 | ||
| Invasive lobular carcinoma | 0.76 (0.72, 0.81) | <.001 | 0.84 (0.77, 0.92) | <.001 |
| Mixed ductal and lobular | 0.81 (0.75, 0.87) | <.001 | 0.84 (0.77, 0.93) | <.001 |
| Inflammatory | 2.00 (1.53, 2.62) | <.001 | 1.06 (1.03, 1.10) | .0003 |
| Laterality | ||||
| Unilateral | 1 | 1 | ||
| Bilateral | 0.48 (0.06, 3.63) | .48 | 0.81 (0.49, 1.34) | .41 |
Abbreviations: aRR, adjusted risk ratio. AJCC, American Joint Committee on Cancer. HR, Hormone Receptor. HER2, Human Epidermal Growth Factor Receptor 2.